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Objectives
We evaluated effectiveness of rituximab, an anti-CD20
monoclonal antibody, in combination with low dose
cyclophosphamide and intravenous (IV) methylpred-
nisolone in three pediatric SLE patients with relapsing
class IV nephritis.
Methods
Patients 1 and 2
Identical twin females with SLE, complicated by biopsy
proven class IV nephritis at age 6-years and treated with
NIH cyclophosphamide protocol (NIHCP), had biopsy
documented Class IV renal flare at age 10-years; unre-
sponsive to mycophenolate mofetil (MMF) and corticos-
teroids.
Patient 3
A 12-year old female with SLE, complicated by biopsy
documented Class IV nephritis and treated with NIHCP,
had 2 further renal flares, which responded to a cumula-
tive dose of 36 grams of cyclophosphamide. At age 16, she
had another biopsy documented class IV renal flare,
despite maintenance with MMF.
All patients received pulse therapy with: IV cyclophospha-
mide 0.5 g/m2 with IV methylprednisolone (IVMP) 250
mg on days 1 and 23; IV rituximab 375 mg/m2 on days 2,
9, 16 and 23.
Results
All 3 patients had a dramatic improvement in urine pro-
tein-creatinine ratios, and normalization of blood pres-
sure. Despite low-dose daily corticosteroids, all patients
had an increase in generalized SLE activity by 4 weeks fol-
lowing rituximab therapy, which responded to re-intro-
duction of MMF. No side effects apart from expected
decrease in B-cell counts were noted.
Conclusion
Rituximab in combination with low dose cyclophospha-
mide and IVMP was effective in controlling recurrent class
IV nephritis in 3 pediatric SLE patients.
Re-introduction of mycophenolate mofetil was required
within 4 weeks following rituximab therapy to maintain
disease remission.
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